Disc Medicine announced its Q1 2026 financial results, highlighting the completion of enrollment for its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), with topline data expected in Q4 2026. The company also plans to present updated Phase 2 data for DISC-0974 in myelofibrosis anemia at the ASCO meeting and expects data from ongoing studies of DISC-3405 in polycythemia vera and sickle cell disease by Q4 2026. Disc Medicine ended Q1 with $730 million in cash, supporting operations into 2029. These milestones position the company for multiple important catalysts later this year.
Borders & Southern Petroleum is progressing discussions with multiple parties to farm out its Darwin oil discovery in the Falkland Islands, amid growing investor interest driven by accelerated development of the Sea Lion oil project. The company owns...
Solana (SOL) has surged more than 24% in the past week and 43% over the last month, reclaiming the $100 price level. Institutional and whale investors, including DeFi Development Corp (DFDV), which added 19,000 SOL to its 2.3 million token holdings, ...
Dunkin' and BARK opened their first official dog drive-thru in Quincy, Massachusetts, on National Dog Day, offering dog treats, limited-edition bandanas, and plush toys inspired by Dunkin's menu. The event supports the Dunkin' Joy in Childhood Founda...
US-listed XRP ETFs attracted $28.14 million on August 26, marking the second-largest daily inflow in 2026, led by Bitwise with $13.12 million. Whale wallets accumulated about 460 million XRP tokens, the strongest since February, signaling strong inst...
At Bitcoin Asia 2026 in Hong Kong, former Binance CEO Changpeng Zhao predicted Bitcoin will overtake gold's significance during the next bull market cycle. While gold's market cap is about $32.4 trillion, Bitcoin currently holds $1.6 trillion, with Z...
